Autres langues Intellia Therapeutics, Inc.

Actions

NTLA

US45826J1051

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 12/05/2026			Varia. 5j.	Varia. 1 janv.
13,99 ^USD	-2,98 %		+5,11 %	+55,62 %

11/05	Intellia Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
11/05	Intellia Therapeutics : perte réduite au premier trimestre malgré un repli du chiffre d'affaires	MT

Autres langues

11/05	Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
11/05	Intellia Therapeutics Q1 Loss Narrows, Revenue Falls
11/05	Earnings Flash (NTLA) Intellia Therapeutics Posts Q1 Net Loss $0.81 a Share, vs. FactSet Est of $0.91 Loss
11/05	Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q1 Revenue $15.0M, vs. FactSet Est of $13.8M
11/05	Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
05/05	Intellia Therapeutics to Participate in Upcoming Investor Conferences
04/05	Intellia Initiates Rolling BLA Submission For In Vivo CRISPR Therapy In Hereditary Angioedema
01/05	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/04	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
27/04	Intellia Therapeutics Launches $150 Million Stock Offering
27/04	Intellia Therapeutics, Inc. has filed an IPO.
27/04	Intellia Announces Proposed Public Offering of Common Stock
27/04	Intellia Therapeutics Starts Rolling FDA Application After Phase 3 Angioedema Trial Meets Primary Endpoint
27/04	Intellia's gene therapy for rare disease cuts swelling attacks in late-stage trial
27/04	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
27/04	Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
27/04	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
27/04	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to Fda for Lonvoguran Ziclumeran as A One-Time Treatment for Hereditary Angioedema
27/04	Intellia Therapeutics Reports Positive Phase 3 Results In Hereditary Angioedema
24/04	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
03/04	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
06/03	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/03	Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran, Hereditary Angioedema Patient-Focused Research at AAAAI 2026
03/03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran